03 Aug Calling all STAGE I, II & III MELANOMA PATIENTS in Canada!
Please participate in this survey regarding preferences for adjuvant treatment of melanoma in Canada. The ANONYMOUS SURVEY will require approximately 30 minutes to complete.
Sponsored by Novartis, the information in this study may be included in research publications and submissions to agencies that evaluate and make recommendations regarding reimbursement of treatments for patients in Canada.
To participate, please CLICK HERE. The survey will remain open for completion until midnight (EST) on Friday, August 17, 2018.
In order to qualify for participation, you must (1) currently reside in Canada, (2) have a current diagnosis of local or regional melanoma (Stage I, II, or III), and (3) be at least 18 years of age. Individuals who reside outside of Canada, do not have melanoma or currently have metastatic melanoma (Stage IV), or are younger than 18 years of age are not eligible to participate.
If you have any questions, you may contact the study manager or the sponsor directly using the contact information below:
|Study Manager||Study Sponsor|
Daniel Stellato, BS
Policy Analysis Inc. (PAI)
Four Davis Court
Brookline, MA 02445
Marroon Thabane, PhD
Manager, Health Economics and Outcomes Research
Oncology Business Unit
385 Bouchard Blvd.
Dorval, Quebec H9S 1A9 CANADA
About Policy Analysis Inc. (PAI)
PAI is a health economics and outcomes research (HEOR) organization providing services to the global biopharmaceutical industry located in Brookline, Massachusetts, USA (https://www.pai2.com).
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide (https://www.novartis.ca/en).